"Novavax Vaccine Demonstrates 90.4% COVID-19 Prevention in Large-Scale Clinical Trials in the US and Others"

[Image source=Reuters Yonhap News]

[Asia Economy Reporter Yu Je-hoon] Novavax's COVID-19 vaccine has shown a 90.4% efficacy rate in large-scale clinical trials conducted in the United States, Mexico, and other regions.

On the 14th, Novavax announced on its website that its NVX-CoV2373 vaccine demonstrated this prevention rate in clinical trials involving 29,960 participants aged 18 and older in the United States, Mexico, and other areas.

According to Novavax, in this trial, one-third of the subjects received a placebo, while two-thirds were vaccinated. As a result, 63 confirmed cases occurred in the placebo group, and 14 cases in the vaccinated group, resulting in a prevention rate of 90.4%. Notably, all 14 cases exhibiting moderate to severe symptoms were observed only in the placebo group.

Meanwhile, Novavax plans to produce 100 million doses of the vaccine monthly by the end of the third quarter and aims to increase this to 150 million doses in the fourth quarter of this year. Stanley Erck, CEO of Novavax, stated, "These clinical results prove that NVX-CoV2373 is highly effective and provides complete protection against moderate and severe infections," adding, "We are urgently working to deliver this to a world still in desperate need of vaccines."

This content was produced with the assistance of AI translation services.